Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Next Previous
Trial Profile

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms ATTAIN

Most Recent Events

  • 18 Aug 2017 Status changed from active, no longer recruiting to discontinued due to poor accrual.
  • 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.
  • 02 Jul 2015 Planned primary completion date changed from 1 Aug 2019 to 1 Jul 2019 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top